

CORPORATE BROCHURE

Vaxxinova

Committed to disease prevention in livestock



va:xx:ino:va

www.vaxxinova.com



Our commitment

Vaxxinova® believes in long-term animal health solutions and professional partnerships. Together with our partners we want to prevent diseases, support antibiotics reduction and help our customers with their performance improvement programs.

Vaxxinova is part of the family-owned EW Group, which operates in over 100 countries in animal genetics, animal nutrition and animal health. The EW Group records consistent international growth and pursues highly progressive goals, based on long-term investment strategies



Our offering

Our long-term high-quality animal health solutions range from diagnostics to preventive solutions and strategies. With our vaccines, we want to provide highly efficacious vaccination solutions that allow for maximum performance.

Licensed vaccines


Vaxxinova provides a high-quality and complete vaccine portfolio which includes all relevant live and inactivated, mono- and combination vaccines. While our registered vaccine portfolio focuses on diseases in poultry and aquaculture, we also aim to provide fitting solutions for major and emerging diseases in ruminants, swine, turkeys and companion animals. Furthermore, we are investing in new vaccine technologies.


Autogenous vaccines

Autogenous vaccines are tailor made vaccines, either from individual sites or from a defined geographical area in case registered vaccines are not available or no longer effective. Vaxxinova has many years of experience in research and development, manufacturing and the application of autogenous vaccines. Vaxxinova can provide both bacterial and viral autogenous vaccines for the intensive livestock production such as poultry, aqua, swine, cattle and turkeys.


vaxxinova.com

Legacy





Though Vaxxinova was officially named and founded in 2010, our predecessors have been in the livestock vaccine and diagnostics business since the 1950s. Vaxxinova can rely on more than 6 decades of expertise in disease prevention for production animals and our products and services are available in more than 60 countries.



Diagnostics

Diagnostics are a vital part of Vaxxinova's technical support, as they ensure proper monitoring. Our technical teams translate diagnostic results in customized vaccination programs. With our diagnostic solutions, Vaxxinova supports the animal health business, both globally and locally, both short-term and long-term.



Research & Development

A sustainable production of animal proteins is of the utmost importance. Our R&D teams therefore work closely together to develop innovative licensed and autogenous vaccines and are working on new vaccine technologies. We help our customers by protecting their animals against known, emerging and new diseases caused by viruses, bacteria and parasites.

Production & Quality Control

With our products, we aim to optimize animal health and animal welfare and to boost performance. Our Production and Quality Control teams in Brazil, Germany, Italy, Japan and the US are dedicated to the manufacturing and quality control of our vaccines. Our high-quality standard procedures, together with formulations, ensure safe and efficacious vaccines.

Vaxxinova worldwide

Our current network comprises production, research & development, sales and diagnostic facilities in 10 countries: Brazil, Chile, Germany, Italy, Japan, Jordan, Norway, the Netherlands, Thailand and the USA.



THE NETHERLANDS

Nijmegen

NORWAY

Bergen

USA

Willmar

BRAZIL

Vargem Grande Paulista, Ibiúna

CHILE

Puerto Varas

GERMANY

Cuxhaven, Leipzig, Münster

ITALY

Brescia, Chignolo Po

JAPAN

Tokyo, Tochigi

JORDAN

Amman

THAILAND

Bangkok

KEY FACTS

- 6 production sites
- 5 diagnostic centers
- 8 R&D sites
- Sales in over 60 countries
- 1000 employees

vaxxinova.com



www.vaxxinova.com

Vaxxinova® International
Transistorweg 5, 6534AT Nijmegen
The Netherlands

+31 (0)24 2048600
info@vaxxinova.com
www.vaxxinova.com

VAXXINOVA, VAXXON AND GOVAXX are registered trademarks of Vaxxinova International B.V. (the Netherlands).

When taking delivery of this brochure you accept the following terms and conditions which apply to the brochure. The information contained in this brochure is provided as is. The contents of this brochure is for general information purposes only and does not constitute any offer or any advice. Vaxxinova International B.V. makes no warranties or representations or other assurance of any kind, whether expressed or implied, regarding the correctness, accuracy, completeness, timelessness, usefulness, fitness for any purpose, reliability or otherwise of the content, details, information, services or products contained in this brochure and/or the use thereof. Any reliance you place on this brochure and the content is strictly at your own risk. Under no event, Vaxxinova International B.V. will be liable for any damage or loss that might arise from the direct or indirect use of any information in this brochure. Vaxxinova International B.V. declines any liability and responsibility for any form of damages or losses, including but not limited to direct, indirect, special, financial, consequential, criminal or incidental loss, including lost profits, lost savings, increased operation costs, loss of customers etcetera, whether based on a failure, tort or any other ground, which might result or relates to the direct or indirect use of any information or other content in this brochure or any other material of Vaxxinova, including but not limited to any actions or decisions based on that information, or which may directly or indirectly arise from any inaccuracies, or incompleteness or errors etcetera contained in any brochure or other material of Vaxxinova.

The rights relating to the brochure, including those of intellectual property, copyright, design, photographs and other are and shall remain the exclusive property of Vaxxinova International B.V. or its licensors. It is not allowed to copy, duplicate or distribute this brochure or its content without the prior written consent of Vaxxinova International B.V. Dutch law applies to this disclaimer.

Version 04, 2020.09.01. Article number: 120541. Design: Haltenbanken.com